Sohail Z. Husain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sohail Z. Husain has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
Monique T. Barakat
Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Stanford University, School of Medicine, Stanford, CA, USA; Division of Gastroenterology and Hepatology, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
8 shared publications- Li Wen
Center for Biomarker Discovery and Validation, National Infrastructures for Translational Medicine (PUMCH), Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, 100730, China
6 shared publications - Asna Khalid
Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Stanford University, School of Medicine, Stanford, CA, USA
5 shared publications - Cheng-Yu Tsai
Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Stanford University, School of Medicine, Stanford, CA, USA
5 shared publications Li Wen
Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
5 shared publications- Ying Ding
Department of Biostatistics University of Pittsburgh Pittsburgh Pennsylvania USA
5 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by SMART-MD Publishing LLC in SMART-MD Journal of Precision Medicine
- Vol. 3 (3) , e275-e280
Asparaginase-Associated Acute Pancreatitis—A Review
Drugs remain a leading cause of acute pancreatitis (AP) in children. Asparaginase is a known cause of AP with reported incidence of up to 19%. The exact pathophysiology of asparaginase-associated pancreatitis (AAP) is unknown. Risk factors include age (older children/adolescents and adults), intermediate risk/high risk acute lymphoblastic leukemia (ALL) and presence of genetic mutations which appear to be an additive risk. It is associated with severe AP with increased morbidity and mortality. Management is usually supportive and first involves stopping the medication, and then management of AP. Incidence of AAP upon rechallenge is high and should be avoided when possible.
- 22 September 2026
- Published by SMART-MD Publishing LLC in SMART-MD Journal of Precision Medicine
- Vol. 3 (3) , e275-e280
Open AccessAsparaginase-Associated Acute Pancreatitis—A Review
Drugs remain a leading cause of acute pancreatitis (AP) in children. Asparaginase is a known cause of AP with reported incidence of up to 19%. The exact pathophysiology of asparaginase-associated pancreatitis (AAP) is unknown. Risk factors include age (older children/adolescents and adults), intermediate risk/high risk acute lymphoblastic leukemia (ALL) and presence of genetic mutations which appear to be an additive risk. It is associated with severe AP with increased morbidity and mortality. Management is usually supportive and first involves stopping the medication, and then management of AP. Incidence of AAP upon rechallenge is high and should be avoided when possible.
- Open Access
- 12 August 2026
- Published by Elsevier in Pancreatology
Induction of acute pancreatitis in adult zebrafish: A reproducible and quantifiable experimental model
- 12 August 2026
- Published by Elsevier in Pancreatology
Open AccessInduction of acute pancreatitis in adult zebrafish: A reproducible and quantifiable experimental model
- Open Access
- 28 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (12)
A lipid-immune network signature defines susceptibility to asparaginase-associated pancreatitis
BACKGROUND: Asparaginase is essential for curing acute lymphoblastic leukemia (ALL), but its use is limited by asparaginase-associated pancreatitis (AAP), a severe and unpredictable toxicity lacking validated prospective biomarkers. We sought to define early systemic molecular features of susceptibility to AAP. METHODS: We performed longitudinal lipidomic and proteomic profiling in two independent pediatric ALL cohorts ( n = 161; 79 AAP cases, 82 controls) using paired blood samples collected before asparaginase exposure and at the end of induction therapy (including a single dose of asparaginase), thereby capturing pre-injury biology rather than consequences of pancreatitis. We applied differential abundance and network-based analyses and integrated lipid-cytokine associations using proteomics. RESULTS: Across cohorts, we identified a reproducible lysophosphatidylcholine-centered (LPC-centered) signature characterized by attenuated induction therapy–associated LPC responses and disruption of LPC coregulation at the network level. Proteomic profiling revealed enrichment of cytokine signaling pathways, and integrative analyses demonstrated altered lipid-cytokine coupling, including a flip in association direction for LPC species and IL-18 between cases and controls. Although IL-18/LPC ratios did not differ globally, elevated postinduction IL-18/LPC ratios identified AAP risk within a protocol-defined very high-risk ALL subgroup (AUC = 0.81). CONCLUSION: These findings support a systems-level model in which failure of coordinated lipid-immune responses under therapeutic stress confers vulnerability to AAP, providing a framework for validation and mitigation strategies. TRIAL REGISTRATION: NCT00400946; NCT01574274; NCT03020030 (parent trials). FUNDING: Servier Pharmaceuticals (IIT-95014-027-USA); SDRC (P30DK116074); Stanford SPARK; Fonds de Recherche du Québec – Santé; Fondation Charles-Bruneau; Leukemia & Lymphoma Society of Canada.
- 28 April 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (12)
Open AccessA lipid-immune network signature defines susceptibility to asparaginase-associated pancreatitis
BACKGROUND: Asparaginase is essential for curing acute lymphoblastic leukemia (ALL), but its use is limited by asparaginase-associated pancreatitis (AAP), a severe and unpredictable toxicity lacking validated prospective biomarkers. We sought to define early systemic molecular features of susceptibility to AAP. METHODS: We performed longitudinal lipidomic and proteomic profiling in two independent pediatric ALL cohorts ( n = 161; 79 AAP cases, 82 controls) using paired blood samples collected before asparaginase exposure and at the end of induction therapy (including a single dose of asparaginase), thereby capturing pre-injury biology rather than consequences of pancreatitis. We applied differential abundance and network-based analyses and integrated lipid-cytokine associations using proteomics. RESULTS: Across cohorts, we identified a reproducible lysophosphatidylcholine-centered (LPC-centered) signature characterized by attenuated induction therapy–associated LPC responses and disruption of LPC coregulation at the network level. Proteomic profiling revealed enrichment of cytokine signaling pathways, and integrative analyses demonstrated altered lipid-cytokine coupling, including a flip in association direction for LPC species and IL-18 between cases and controls. Although IL-18/LPC ratios did not differ globally, elevated postinduction IL-18/LPC ratios identified AAP risk within a protocol-defined very high-risk ALL subgroup (AUC = 0.81). CONCLUSION: These findings support a systems-level model in which failure of coordinated lipid-immune responses under therapeutic stress confers vulnerability to AAP, providing a framework for validation and mitigation strategies. TRIAL REGISTRATION: NCT00400946; NCT01574274; NCT03020030 (parent trials). FUNDING: Servier Pharmaceuticals (IIT-95014-027-USA); SDRC (P30DK116074); Stanford SPARK; Fonds de Recherche du Québec – Santé; Fondation Charles-Bruneau; Leukemia & Lymphoma Society of Canada.
- 2 February 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (4) , 525-531
Long-term disease progression in pediatric acute recurrent and chronic pancreatitis: A report from INSPPIRE
- 2 February 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (4) , 525-531
Long-term disease progression in pediatric acute recurrent and chronic pancreatitis: A report from INSPPIRE
- 5 October 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (7) , 1216
Reply to the Letter to the Editor "Why is the rectal route for NSAIDs favorable for preventing post-ERCP pancreatitis"
- 5 October 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (7) , 1216
Reply to the Letter to the Editor "Why is the rectal route for NSAIDs favorable for preventing post-ERCP pancreatitis"
- 5 February 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (4) , 491-498
Why is the rectal route for NSAIDS favorable for preventing post-ERCP pancreatitis?
- 5 February 2025
- Published by Elsevier in Pancreatology
- Vol. 25 (4) , 491-498
Why is the rectal route for NSAIDS favorable for preventing post-ERCP pancreatitis?
- Open Access
- 23 December 2024
- Published by Wiley in United European Gastroenterology Journal
- Vol. 13 (1) , 78-85
Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis: Novel Mechanisms and Prevention by Drugs
Endoscopic retrograde cholangiopancreatography (ERCP) is becoming more common than first‐line therapy for pancreaticobiliary duct disorders. However, post‐ERCP pancreatitis is the most common complication of ERCPs, and affects about 10% of cases. In this review, we provide an overview of the mechanisms purported to cause post‐ERCP pancreatitis as well as associated risk factors. We discuss measures that are in practice for post‐ERCP pancreatitis pharmaco‐prophylaxis, along with advances in the pipeline. We emphasize that there is still a pressing need to narrow the incidence of post‐ERCP pancreatitis and that a mechanistic approach may reveal the greatest benefit from utilizing a combination of targets.
- 23 December 2024
- Published by Wiley in United European Gastroenterology Journal
- Vol. 13 (1) , 78-85
Open AccessPost Endoscopic Retrograde Cholangiopancreatography Pancreatitis: Novel Mechanisms and Prevention by Drugs
Endoscopic retrograde cholangiopancreatography (ERCP) is becoming more common than first‐line therapy for pancreaticobiliary duct disorders. However, post‐ERCP pancreatitis is the most common complication of ERCPs, and affects about 10% of cases. In this review, we provide an overview of the mechanisms purported to cause post‐ERCP pancreatitis as well as associated risk factors. We discuss measures that are in practice for post‐ERCP pancreatitis pharmaco‐prophylaxis, along with advances in the pipeline. We emphasize that there is still a pressing need to narrow the incidence of post‐ERCP pancreatitis and that a mechanistic approach may reveal the greatest benefit from utilizing a combination of targets.
- Open Access
- 7 November 2024
- Published by Wiley in United European Gastroenterology Journal
- Vol. 13 (3) , 472-473
Differences in the burden of pediatric pancreatitis across countries and regions: One size does not fit all
- 7 November 2024
- Published by Wiley in United European Gastroenterology Journal
- Vol. 13 (3) , 472-473
Open AccessDifferences in the burden of pediatric pancreatitis across countries and regions: One size does not fit all
- Open Access
- 9 February 2024
- Published by Wolters Kluwer Health in Journal of Pancreatology
- Vol. 7 (1) , 21-27
Exploiting open source omics data to advance pancreas research
The “omics” revolution has transformed the biomedical research landscape by equipping scientists with the ability to interrogate complex biological phenomenon and disease processes at an unprecedented level. The volume of “big” data generated by the different omics studies such as genomics, transcriptomics, proteomics, and metabolomics has led to the concurrent development of computational tools to enable in silico analysis and aid data deconvolution. Considering the intensive resources and high costs required to generate and analyze big data, there has been centralized, collaborative efforts to make the data and analysis tools freely available as “Open Source,” to benefit the wider research community. Pancreatology research studies have contributed to this “big data rush” and have additionally benefitted from utilizing the open source data as evidenced by the increasing number of new research findings and publications that stem from such data. In this review, we briefly introduce the evolution of open source omics data, data types, the “FAIR” guiding principles for data management and reuse, and centralized platforms that enable free and fair data accessibility, availability, and provide tools for omics data analysis. We illustrate, through the case study of our own experience in mining pancreatitis omics data, the power of repurposing open source data to answer translationally relevant questions in pancreas research.
- 9 February 2024
- Published by Wolters Kluwer Health in Journal of Pancreatology
- Vol. 7 (1) , 21-27
Open AccessExploiting open source omics data to advance pancreas research
The “omics” revolution has transformed the biomedical research landscape by equipping scientists with the ability to interrogate complex biological phenomenon and disease processes at an unprecedented level. The volume of “big” data generated by the different omics studies such as genomics, transcriptomics, proteomics, and metabolomics has led to the concurrent development of computational tools to enable in silico analysis and aid data deconvolution. Considering the intensive resources and high costs required to generate and analyze big data, there has been centralized, collaborative efforts to make the data and analysis tools freely available as “Open Source,” to benefit the wider research community. Pancreatology research studies have contributed to this “big data rush” and have additionally benefitted from utilizing the open source data as evidenced by the increasing number of new research findings and publications that stem from such data. In this review, we briefly introduce the evolution of open source omics data, data types, the “FAIR” guiding principles for data management and reuse, and centralized platforms that enable free and fair data accessibility, availability, and provide tools for omics data analysis. We illustrate, through the case study of our own experience in mining pancreatitis omics data, the power of repurposing open source data to answer translationally relevant questions in pancreas research.
- 24 September 2023
- Published by Elsevier in Pancreatology
- Vol. 23 (7) , 777-783
Rectal administration of tacrolimus protects against post-ERCP pancreatitis in mice
- 24 September 2023
- Published by Elsevier in Pancreatology
- Vol. 23 (7) , 777-783
Rectal administration of tacrolimus protects against post-ERCP pancreatitis in mice